公开(公告)号：US12296285B2

公开(公告)日：2025-05-13

申请号：US17631897

申请日：2020-07-30

Applicant: UCB BIOPHARMA SRL

Inventor： Neil Alan Watson ,  Curtis William Phippen

IPC: C07K1/18 ,  B01D15/38 ,  C07K1/22 ,  C07K16/06 ,  C07K16/12

Abstract: The invention relates to the field of manufacturing recombinant antibody molecules. In particular, methods of purifying such recombinant antibody molecules are provided wherein imidazole or an imidazole-analogue is added during the elution of the recombinant antibody molecule from an affinity chromatography resin, such as a protein-A-based resin.

公开(公告)号：US20250121301A1

公开(公告)日：2025-04-17

申请号：US19002879

申请日：2024-12-27

Applicant: UCB BIOPHARMA SRL

Inventor： ANNICK GERVAIS ,  JOEL DUBISY

IPC: B01D15/32 ,  B01D15/16 ,  G01N30/34 ,  G01N30/88

Abstract: The current application provides a rapid and simple method for measuring residual pDADMAC in a sample containing a recombinant protein of interest based on the combination of use of reversed-phase hydrophobic interaction HPLC and charged aerosol detection.

公开(公告)号：US20250073179A1

公开(公告)日：2025-03-06

申请号：US18282554

申请日：2022-03-17

Applicant: UCB BIOPHARMA SRL

Inventor： SARAH MARQUETTE ,  CHRISTIAN GRANDFILS ,  JÉRÔME HURLET

IPC: A61K9/70 ,  A61K45/06 ,  A61K47/10 ,  A61K47/59 ,  B33Y80/00

Abstract: The invention relates to the field of pharmaceutical compositions comprising proteins as therapeutic active ingredient. More particularly it is directed to di-block or multi-block copolymers used as excipients, and in particular as stabilizer, in protein-containing dried compositions, filaments obtained from these dried compositions, implantable drug delivery device formed from these filaments and to methods of producing such compositions, filaments and devices.

公开(公告)号：US20250026856A1

公开(公告)日：2025-01-23

申请号：US18711331

申请日：2022-11-17

Applicant: UCB BIOPHARMA SRL

Inventor： Timothy Scott JOHNSON ,  John ATKINSON ,  Jorg Hans Wilhelm DISTLER ,  David John ABRAHAM

IPC: C07K16/40 ,  A61P17/00

Abstract: The present invention relates to an anti-transglutaminase type 2 (TG2) antibody for use in the treatment of a scleroderma disease, such as localized or systemic scleroderma.

公开(公告)号：US20240228082A1

公开(公告)日：2024-07-11

申请号：US18561759

申请日：2022-05-18

Applicant: UCB BIOPHARMA SRL

Inventor： SEBASTIEN DASNOY ,  LAURA SIMONIN

IPC: B65B3/00 ,  G01F22/00

CPC classification number: B65B3/003 ,  G01F22/00

Abstract: The invention relates to the pharmaceutical field and in particular to methods related to the filling of containers containing liquid-in-vial drug products.

公开(公告)号：US12018021B2

公开(公告)日：2024-06-25

申请号：US16973701

申请日：2019-06-20

Applicant: UCB Biopharma SRL

Inventor： Pfrafulkumar Tulshibhai Chovatia ,  Rickki Lee Connelly ,  Richard Jeremy Franklin ,  Gregory William Haslett ,  Alistair James Henry ,  James Madden ,  Judi Charlotte Neuss ,  Timothy John Norman ,  Oliver Philps ,  William Ross Pitt ,  Konstantinos Rampalakos ,  Matthew Duncan Selby ,  Selvaratnam Suganthan ,  Giancarlo Trani ,  Zhaoning Zhu

IPC: C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

CPC classification number: C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

公开(公告)号：US20240123065A1

公开(公告)日：2024-04-18

申请号：US18394323

申请日：2023-12-22

Applicant: UCB BIOPHARMA SRL

Inventor： Sandrine Durran ,  Andrew Jeffrey Yates

IPC: A61K39/395 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C07K16/24

CPC classification number: A61K39/39591 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C07K16/244 ,  C07K2317/76

Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.

公开(公告)号：US20240083925A1

公开(公告)日：2024-03-14

申请号：US18267946

申请日：2021-12-16

Applicant: UCB Biopharma SRL

Inventor： Ali Ates ,  Celal Ates ,  Laurent Provins

IPC: C07F9/6558 ,  C07D401/06

CPC classification number: C07F9/65583 ,  C07D401/06

Abstract: The present invention relates to a prodrug of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone, which prodrug is represented by formula (II).

公开(公告)号：US20240067758A1

公开(公告)日：2024-02-29

申请号：US18255213

申请日：2021-12-06

Applicant: UCB BIOPHARMA SRL

Inventor： Joseph Michael David RASTRICK ,  John Paul SILVA ,  Daniel John LIGHTWOOD ,  Ralph ADAMS ,  Roger Thomas PALFRAMAN ,  Kerry Louise TYSON ,  Peter Charles ELLIOTT ,  Seema MAYANK ,  Andrea Julie CROSBY ,  Emily Mary Cairistine BARRY ,  Seppe Frans Roman LEYSEN ,  Zainab AHDASH

IPC: C07K16/46 ,  C12N15/63 ,  A61P17/00

CPC classification number: C07K16/468 ,  C12N15/63 ,  A61P17/00 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2317/565 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/14

Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.

公开(公告)号：US20240043400A1

公开(公告)日：2024-02-08

申请号：US18265156

申请日：2021-12-01

Applicant: UCB Biopharma SRL

Inventor： Ali Ates ,  Pierre Burssens ,  Adrian Hall ,  Laurent Provins ,  David Skolc ,  Anne Valade

IPC: C07D401/06 ,  C07D217/04 ,  C07D471/04 ,  C07D401/10

CPC classification number: C07D401/06 ,  C07D217/04 ,  C07D471/04 ,  C07D401/10

Abstract: The present invention relates to octahydroisoquinolinyl derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.